GLP-1 drugs versus research peptides category boundaries | Healthcare Discovery
| |

The Peptide Boundary Problem: Why GLP-1 Drugs, Compounded Medication, Research Peptides, and Longevity Claims Cannot Share One Funnel

A source-backed GLP-1 Intelligence Hub guide separating FDA-approved prescription drugs, compounded medication, investigational metabolic drugs, research-use peptides, longevity-clinic claims, and supplement/wellness products.

A clinician reviewing a telehealth consultation screen and transparency checklist beside an unbranded medication shipment box
| |

The GLP-1 Telehealth Transparency Scorecard: What a Platform Should Show Before You Trust It

A 20-point, source-backed framework for evaluating what a GLP-1 telehealth service discloses about medication identity, clinical accountability, pharmacy source, full cost, follow-up, claims, reviews, and commercial influence.